Table of Contents
UPDATE: To Watch the Replay of Kyle’s Option Rocket Webinar
You’ll receive your replay link in a few minutes.
Take action now: On May 24th at 8 PM Eastern. I’ll be releasing a new option strategy I’m calling I.G.N.I.T.E. I’ll also be showing how you can use a simple option strategy to hit huge percentage returns in all types of stocks.
The doors are almost shut because we have too many registrants, so be sure to secure your seat right now!
Today I added to my position in GBT, which bounced very nicely. The FDA gave some new guidelines saying that they were going to be more lenient approving gene therapy drugs – which GBT is a part of. So, we saw shares spike and later on in the session it got some bullish option activity as well!
I’ll be more active here the rest of this week and will be adding some more names to our watch list tomorrow!
Just a reminder, charts and targets are updated every Monday morning!
—– Related —–
This book has helped thousands of other traders learn the basics of biotech, and how to easily spot winning trades.
Whether you are new trader or a 30-year veteran, this book will help you find stocks that are primed to make parabolic moves. These strategies are Kyle’s secret weapons that have help him net over $3 Million in profits…and they are all yours for free.
This is normally $97.00, but it’s yours FREE!
Catalyst Swing names (1 – 4 week holds) I am watching…
Idera Pharmaceuticals (IDRA)
Catalyst Dates: Phase 2 data due out June 4th and another Phase 2 data readout in June
Buy Zone: $1.75 to $1.95
Profit Zone: $2.20 or higher
Stop Zone: $1.70 or below
Aquinox Pharmaceuticals (AQXP)
Catalyst Dates: Phase 3 data due out in the third quarter
Buy Zone: $12.00 to $13.00
Profit Zone: $16.00 or higher
Stop Zone: $11.50 or below
Bellerophon Therapeutics (BLPH)
Catalyst Dates: Interim Phase 3 data release in the middle of 2018 (likely late June or July)
Buy Zone: $2.20 to $2.40
Profit Zone: $2.75 or higher
Stop Zone: $2.10 or below
Durect Corporation (DRRX)
Catalyst Dates: Advisory Committee meeting on June 26th, FDA Approval dates on July 28th and August 7th.
Buy Zone: $1.75 to $2.00
Profit Zone: $2.40 or higher
Stop Zone: $1.65 or below
Array BioPharma (ARRY)
Catalyst Dates: Phase 3 data due out June 20-23. FDA approval date of June 30 as well.
Buy Zone: $14.50 to $15.50
Profit Zone: $18.00 or higher
Stop Zone: $14.00 or below
Global Blood Therapeutics (GBT)
Catalyst Dates: Phase 3 data likely due out in June. Officially in the “first half”
Buy Zone: $46.00 to $48.00
Profit Zone: $54.00 or higher
Stop Zone: $44.00 or below
Pluristem Therapeutics (PSTI)
Catalyst Dates: Phase 2 data due out to be published in June.
Buy Zone: $1.30 to $1.45
Profit Zone: $1.80 or higher
Stop Zone: $1.20 or below
Marinus Pharmaceuticals (MRNS)
Catalyst Dates: Phase 2 data due out in the third quarter. Two other Phase 2 datas due out in the fourth quarter.
Buy Zone: $4.25 to $4.75
Profit Zone: $6.00 or higher
Stop Zone: $4.00 or below
Cytokinetics Incorporated (CYTK)
Catalyst Dates: Phase 2 data due out June 16
Buy Zone: $8.50 to $9.00
Profit Zone: $10.00 or higher
Stop Zone: $7.40 or below
Catalyst Dates: Phase 3 data due late June or early July
Buy Zone: $39.50 to $40.50
Profit Zone: $45.00 or higher
Stop Zone: $37.50 or below
Catalyst Biosciences (CBIO)
Catalyst Dates: Phase 2 data in July
Buy Zone: $26.50 to $28.50
Profit Zone: $33.00 or higher
Stop Zone: $25.00 or below
Pain Therapeutics (PTIE)
Catalyst Dates: Advisory Committee Meeting June 26th and FDA approval date of August 7th
Buy Zone: $7.50 to $8.25
Profit Zone: $9.50 or higher
Stop Zone: $7.00 or below
[Ed.note: Kyle Dennis runs BiotechBreakouts.com. He is an event-based trader, who prefers low-priced and small-cap biotech stocks.